ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS, gemaakt in 2005 (de Verenigde Staten van Amerika), over van de 496 zustermerken en 17478 concurrerende merken. Het merk ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS is eigendom van BRISTOL-MYERS SQUIBB COMPANY, een bedrijf dat is vermeld in New York. De sector van ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS is Geneesmiddelenfabrikanten.

ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS is een handelsmerk van BRISTOL-MYERS SQUIBB COMPANY (BMY) nieuws

Internationaal depot : 2005 Bedrijfssectoren Geneesmiddelenfabrikanten

Alle nieuws Marketscreener Logo
BRISTOL-MYERS SQUIBB COMPANY (ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS)

loader
Beurs: Meer informatie over BRISTOL-MYERS SQUIBB COMPANY (ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS) Marketscreener Logo